Novo Nordisk

Stock futures dipped as markets await key economic data, including the jobs report and CPI, after the Dow breached 50,000. Tech stocks and Bitcoin showed resilience after recent volatility. Pharmaceutical giant Novo Nordisk is suing Hims & Hers over alleged unauthorized distribution of compounded obesity drugs. Meta faces two major trials concerning child safety and the mental health impact of its platforms. Meanwhile, Gen Z’s embrace of 2016 aesthetics signals a “nostalgia economy” driven by economic uncertainty.

Stock futures suggest a positive open despite recent market dips. Investors await key developments: Disney names a new CEO, Josh D’Amaro, though its stock has struggled. Chipotle faces declining customer traffic, impacting its shares. The government reopens, but funding for Homeland Security remains uncertain. Novo Nordisk forecasts slower growth, while Eli Lilly soars on a strong outlook. Nvidia’s CEO denies any issues with OpenAI, highlighting their collaboration.

UBS reported a strong earnings surge, exceeding expectations with a 56% profit jump and announcing a significant share buyback. In contrast, Novo Nordisk faces headwinds, warning of slower growth due to pricing pressures and increased competition, despite new product developments. Broader markets experienced a tech sell-off, impacting software and private credit sectors, with AI disruption concerns weighing on valuations. Meanwhile, a government shutdown was averted, and key developments include Nvidia-OpenAI partnership reassurances, Elon Musk’s empire consolidation, a Fed leadership transition, and gold’s continued ascent.